KLRK1 and glioblastoma: Glioblastoma cells expressing disialoganglioside GD2 and ligands binding to NKG2D are attacked by engineered NK cells expressing the GD2- and NKG2D-based CARs, which then locally release an antibody fragment blocking the activity of CD73 to decrease the concentration of adenosine.